Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177lu-labeled di-hsg peptide imp288
- Development stage
- Phase 1
- Lead developer
- Gilead Sciences
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
177Lu-labeled di-HSG peptide IMP288 is a radiolabeled synthetic hapten-peptide designed for use in pretargeted radioimmunotherapy (PRIT) of cancer. It consists of a divalent histamine-succinyl-glycine (HSG) hapten-peptide conjugated to the macrocyclic chelator DOTA, which stably binds the therapeutic radionuclide lutetium-177 (¹⁷⁷Lu)[1][3][5]. The drug is administered after a bispecific monoclonal antibody that targets both a tumor-associated antigen (such as carcinoembryonic antigen [CEA] or TROP2) and HSG. After the antibody localizes to tumor tissue and clears from circulation, 177Lu-IMP288 is injected; it rapidly binds to the prelocalized antibody at the tumor site while unbound molecules are quickly excreted[7]. Lutetium-177 emits medium-energy beta particles suitable for treating small-volume disease with minimal radiation exposure to normal tissues[3][7]. This approach allows high tumor-to-normal tissue ratios and enables dosimetry-based personalized dosing[5][6]. Clinical studies have focused on advanced colorectal cancer and prostate cancer expressing CEA or TROP2 antigens[5][6][9].
- Other names
- DOTA-di-HSG peptide IMP288177Lu-DOTA-di-HSG-IMP288
02
Targets
Histamine-succinyl-glycine binding site (Anti-HSG)
Beyond the preview
Go deeper on 177lu-labeled di-hsg peptide imp288.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177lu-labeled di-hsg peptide imp288.